Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2028

Conditions
Esophageal Squamous Cell CarcinomaNeoadjuvant Chemoimmunotherapy
Interventions
DRUG

neoadjuvant anti-PD-1 plus chemotherapy

"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER